Background: Covid-19 pandemic is affecting health systems around the world. People living with Non-Communicable Diseases (NCDs) are affected the most. Cancer care activities are disrupted in terms of preventive, early detection, diagnosis, treatment and follow-up The aim of. Aim: study is to know the magnitude of discomfort to patients due to COVID-19 lockdown with respect to Hospital accessibility and Patient's perspective. Study was conducted at Kidwai Memorial Institute of Oncology (KMIO). Longitudinal data wasMaterials and Methodology: collected to know the effect of COVID-19 on Cancer Care. Data was collected from all departments. Trend from January 2020 to December 2020 was observed. The new registration decreased in April and July by around 50% and an increasing trend was observed from August. TheResults: same trend was observed in Diagnostic investigations. A decreasing trend in Admission was observed from April-2020. The number of surgeries performed decreased to more than 50% in the month of April, May and July-2020. Radiotherapy treatments reduced by around 50% in the month of April and July. 53.2% decrease in Chemotherapy cycles was observed in April and July. The Cancer care in terms of diagnosis andConclusion: treatment was affected during the April and July months and it subsequently improved from August-2020. Although the service was available, there was a decrease in the number of patients seeking care for obvious reasons such as non-availability of transport and economic reasons in seeking Cancer care.
Introduction: Breast cancer is one of the most common cancer among Indian Women. The age adjusted rate (AAR) of Breast cancer is 42.1/100000 women in Bengaluru and it is the leading site of cancer in Bengalurian females. The hospital based cancer registry was established in 1983 and is registering around 800 Breast cancer cases per year. Most of them were diagnosed with late stage. The objective of this study is to evaluate Pattern of Care and estimate the Survival rate with respect to different stages, Treatment modalities, ER, PR, HER-2 Status of breast cancer treated only at Kidwai Cancer Institute. A retrospective cohort study was Methodology carried out with 191 Carcinoma Breast cases at a Regional Cancer Centre (Kidwai Memorial Institute of Oncology), Bengaluru. The study started from 2006-2007 and was followed-up until the end of 2020. Five-year survival (60 Months) probabilities were estimated using the Kaplan-Meier and loss adjusted survival analysis method for less than 80% follow-up group for ten years. The log rank test was used to compare the survival between the factors. The overall observed survival rates at 5years Results (60 months) was 72.7%. When analysis was conducted for specic stages, Stage II, Stage III and Stage IV survival rates are 95%, 67% and 17% respectively and is statistically signicant (p<0.001), 39 Patients were dead and 13 Patients were lost for follow-up. The overall survival rate at 10 years was 62.4% and lost for follow-up was 26.5% and death was 27.7%, the Kaplan Meier analysis was unable to be carried out as more than 20% censored cases were seen, hence loss adjusted survival analysis was carried out for 10 years. 89 Patients were alive, 52 patients were dead and 50 patients were lost for follow-up at 10 years. Conclusion: In surgical histopathological nding Estrogen receptor, Progesterone receptor and HER-2 status did not have signicant impact on survival of patients. The post-operative Radiotherapy and combination of modalities of treatment had signicant effect on the long term survival of the patients after adjusting for disease stage.
India and the rest of the world are experiencing an outbreak of the COVID- 19 virus. WHO has declared 2019 novel coronavirus disease (COVID19), a public health emergency of international concern. (1) Palliative treatment compromises a major portion of radiation treatments in cancer. (2) Metastatic or palliation treatment presents a unique challenge in resource-limited settings as ours and early treatment to alleviate their symptoms and disease is the need of the hour to prevent further morbidity and mortality. These patients are usually more cachexic with low immunity and more prone to infection of COVID-19 than the normal population, here their treatment has to be expedited and their visits to the hospital to be minimized to prevent infection with COVID. (3) We reviewed the best evidence and recommended best practices for the treatment of common oncologic emergencies with more emphasis on balancing the risk of infection with the COVID-19 virus and the potential morbidity of delaying treatment. In COVID -19 Era pandemic, the use of hypofractionated radiation therapy for palliative patients for oncologic emergencies achieves intended functional outcomes without compromising care
ulceration (n = 1) and trismus (n = 1). Four of these 5 patients did not have evidence of concurrent local recurrence. Conclusion: HN SBRT has been largely reported in the re-irradiation setting, however, SBRT may have greater utility in the palliative management of previously untreated HNC patients. Despite the advanced age and performance status noted in this group of patients with mucosal SCC of the head and neck, who were not eligible for conventional RT, SBRT was associated with low local failure rates and reasonable toxicity profile. A randomized controlled trial is warranted to confirm the efficacy of HN SBRT in this setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.